Cephalon distancing Provigil from Plavix

Cephalon believes that its settlements with four generic manufacturers over patents for the excessive sleepiness therapy Provigil are not comparable to Bristol-Myers Squibb and Sanofi-Aventis' recently rejected settlement with Apotex over Plavix generics. When asked by "The Pink Sheet" whether FTC granted antitrust clearance to the deals, firm responds: "Our case is unrelated to the Bristol-Myers case. Cephalon is not subject to a consent decree that would require FTC approval of settlements. Similarities end at the fact that we both have made settlements with generic companies." The Provigil agreements are subject to antitrust clearance and FTC has expressed concern about the deals (1"The Pink Sheet" May 1, 2006, p. 10)...